Detalles de la búsqueda
1.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med
; 366(9): 799-807, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22375971
2.
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Haematologica
; 100(4): 479-88, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25616577
3.
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Haematologica
; 99(2): 292-8, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23911705
4.
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Br J Haematol
; 161(4): 508-16, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23480528
5.
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Haematologica
; 98(12): 1865-71, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24038026
6.
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
J Hematol Oncol
; 10(1): 55, 2017 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28228106
7.
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Clin Lung Cancer
; 15(3): 188-196.e2, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24560012
8.
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
J Clin Oncol
; 31(10): 1285-92, 2013 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23423753
Resultados
1 -
8
de 8
1
Próxima >
>>